Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  Disease Landscape and Forecast Insights

Diabetic Macular Edema/Diabetic Retinopathy | Unmet Need | Diabetic Macular Edema | US/FR/DE/UK | 2021

Login to access report north_east
Contact sales account_box

Diabetic macular edema (DME) represents the second-largest ophthalmology market for intravitreal anti-VEGF therapies, including Roche / Novartis’s Lucentis and Regeneron / Bayer’s market-leading Eylea. Because these therapies require regular injections to be effective, they present a major delivery burden that often impacts patient compliance. The corticosteroid implants Ozurdex (AbbVie) and Iluvien (Alimera Sciences) provide a longer duration of action between doses but are associated with side effects that relegate them to later-line treatment. Therefore, unmet need remains for therapies that provide strong efficacy for improving visual acuity with less-frequent dosing.

QUESTIONS ANSWERED

  • What are the key treatment drivers and goals for DME that influence ophthalmologists’ choice of therapies?
  • What drug attributes are key influences, which have limited impact, and which are hidden opportunities in the DME market?
  • How do ophthalmologists perceive the performance of current therapies on key treatment drivers and goals for DME?
  • What are the prevailing areas of market opportunity in the treatment of DME? Will emerging therapies, such as Novartis’s Beovu or Roche’s faricimab, fulfill these unmet needs?
  • What trade-offs are acceptable to U.S. and European ophthalmologists for a hypothetical DME drug?

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S. and 30 European ophthalmologists fielded in February 2021

Key companies: Roche / Genentech, Regeneron / Bayer, Novartis, AbbVie (Allergan), Alimera Sciences, Kodiak Sciences

Key drugs: Lucentis, Eylea, Avastin, Ozurdex, Iluvien, Beovu, ranibizumab port delivery system, high-dose aflibercept, KSI-301, faricimab

Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Chronic Obstructive Pulmonary Disease – Unmet Need – Unmet Need – Severe to Very Severe Chronic Obstructive Pulmonary Disease (US EU)
The severe to very severe chronic COPD market is crowded, with numerous LAMA, LABA/ICS, LABA/LAMA, and triple LABA/LAMA/ICS inhalers competing for use. Although dual and triple longacting…
north_east
Report
Diabetic Macular Edema / Diabetic Retinopathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Diabetic Macular Edema (US)
Diabetic macular edema (DME) is a serious complication of diabetic retinopathy caused by persistently elevated blood glucose levels. Without timely treatment, DME can progress to significant vision…
north_east
Report
Multiple System Atrophy – Unmet Need – Multiple System Atrophy (US/EU) – Unmet Need – Multiple System Atrophy (US/EU)
Multiple system atrophy (MSA) is a rare, rapidly progressing neurodegenerative synucleinopathy that disrupts movement, balance, and autonomic function. Current management comprises only symptomatic…
north_east
Report
Sarcoidosis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Sarcoidosis (US)
Sarcoidosis is a multisystem inflammatory disorder marked by granuloma formation, most often affecting the lungs, lymph nodes, skin, eyes, and heart. Corticosteroids such as prednisone are the…
north_east
Report
Bladder Cancer and Upper Tract Urothelial Carcinoma – Unmet Need – Unmet Need – Unresectable Locally Advanced or Metastatic Bladder Cancer (US/EU)
The unresectable locally advanced or metastatic bladder cancer treatment landscape continues to evolve, driven by the integration of immunotherapy, targeted agents, and antibody–drug conjugates (…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east